ABSTRACT Zika virus (ZIKV), a flavivirus transmitted by mosquitoes, was an almost neglected pathogen until its introduction in the Americas in 2015 and its subsequent explosive spread throughout the continent, where it has infected millions of people. The virus has caused social and sanitary alarm, mainly due to its association with severe neurological disorders (Guillain-Barré syndrome and microcephaly in fetuses and newborns). Nowadays, no specific antiviral therapy against ZIKV is available. However, during the past months, a great effort has been made to search for antiviral candidates using different approaches and methodologies, ranging from testing specific compounds with known antiviral activity to the screening of libraries with hundreds of bioactive molecules. The identified antiviral candidates include drugs targeting viral components as well as cellular ones. Here, an updated review of what has been done in this line is presented.
TABLE 1 Compounds with anti-ZIKV activity

Category
Compound
Biological system a
Reference(s) or source
Nucleotide/nucleoside analogs and pyrimidine synthesis inhibitors BCX4430, 7-deaza-2=-CMA, 2=-CMA, 2=-CMC, 2=-CMG, 2=-CMU, NITD008, CID91632869, finasteride, brequinar, 6-azauridine, 5=-fluorouracil, gemcitabine, sofosbuvir
Cell culture, biochemical assays, and mice 13-18, 20, 23-26 Viral protease inhibitors poration of mutations in the viral genome, thereby increasing error-prone replication (22) . Adcock and coworkers (23) used a cell-based assay for the high-throughput screening of broad-spectrum antiviral compounds as ZIKV inhibitors. They reported that drugs that inhibit purine synthesis (ribavirin and mycophenolic acid [MPA] ) were toxic or did not reduce ZIKV multiplication in Vero cells. On the contrary, the pyrimidine synthesis inhibitors tested (NITD008, CID 91632869, finasteride, brequinar, and 6-azauridine) were able to reduce viral multiplication to different levels, with EC 50 s ranging from submicromolar (brequinar) to 3.2 M (6-azauridine). Remarkably, 6-azauridine, an anticancer drug and viral inhibitor, was also identified (EC 50 , 2.3 M; SI, Ͼ33.3) in another screening (24) . Regarding NITD008, this compound also exhibited antiviral activity in A129 mice deficient in type I interferon receptor treated with 50 mg/kg/day of the drug, as all vehicle-treated mice died within 12 days after ZIKV infection, whereas 50% of the NITD008-treated animals survived without developing any neurological signs (25) . In this line, it has also been reported that gemcitabine, a nucleoside that interferes with de novo pyrimidine biosynthesis, inhibited ZIKV multiplication (EC 50 , 1 M; SI, Ͼ1,000) by interfering with the transcription of viral RNA (26) . Similarly, another screening also identified the thymidylate synthetase inhibitor 5-fluorouracil, an anticancer drug, as a potent inhibitor of ZIKV multiplication (EC 50 , 14.3 M; SI, Ͼ2.5)(24), further supporting pyrimidine synthesis inhibitors as potential antiviral candidates against ZIKV.
Methyltransferase and protease inhibitors. The NS5 protein of ZIKV exhibits not only RdRp activity, but also displays a methyltransferase domain responsible for capping the 5= end of viral genomic RNA. This enzymatic activity has just started to be explored as a potential antiviral target to combat ZIKV (27) (28) (29) . ZIKV proteins other than NS5 also constitute potential druggable antiviral targets. This is the case with the N2B-NS3 trypsin-like serine protease, which plays a key role in virus replication by contributing to viral polyprotein processing (30) , or with NS3 helicase activity (31) . Due to the relevance of NS2B-NS3 function in the ZIKV life cycle, the search for inhibitors of the enzymatic activity of this complex is at the front line of antiviral discovery against ZIKV (30, (32) (33) (34) . For instance, taking advantage of a previous work that identified inhibitors of the HCV protease by high-throughput screening of over 40,000 compounds (35) , the same group have recently analyzed 71 of these nonpeptidic small molecules against ZIKV and found that 10 of them showed 50% inhibitory concentrations (IC 50 s) lower than 50 M, with IC 50 s of 5.2 M and 4.1 M for compounds 2 and 3, respectively (30) . Additionally, the structure of the NS2B-NS3 complex has been resolved under different circumstances, including in complex with a peptidomimetic boronic acid inhibitor (36) .
Therapeutic antibodies and virucidal compounds. The administration of specific potent neutralizing antibodies appears as a potential strategy for the treatment of flavivirus infections (37) . In the case of ZIKV, it has been recently shown that passive transfer of human neutralizing antibodies through the intraperitoneal inoculation of pregnant mice suppressed ZIKV replication, inhibited cell death, reduced the number of infected neural progenitor cells (NPC) in fetal brains, and prevented microcephaly (38, 39) . Furthermore, the treatment of mice with a monoclonal antibody against domain III of the envelope protein of ZIKV is sufficient to protect mice from lethal ZIKV infection (40) . Overall, these studies support the potential of anti-ZIKV strategies based on the usage of therapeutic antibodies.
In addition to therapeutic antibodies, other compounds targeting the viral particle, such as epigallocatechin gallate (EGCG), a polyphenol present in many natural products, exhibit anti-ZIKV activity (EC 50 
HOST-TARGETING ANTIVIRALS
Apart from drugs targeting viral components, those targeting cellular factors directly involved in the viral life cycle may also be useful, since their effect is less prone to evasion by mutations in the viral genome that frequently appear in RNA viruses. In this line, 2,000 compounds from a library of FDA-approved drugs, as well as molecules known to be bioactives, have been tested by means of a microscopy-based assay to uncover inhibitors of ZIKV infection (42) . By using human osteosarcoma cells (U2OS), it was shown that up to 38 molecules blocked flavivirus infection, including nanchangmycin (IC 50 , 0.1 M), a natural product of Streptomyces nanchangensis that was shown to have insecticidal activity against silkworms and anti-bacterial activity in vitro, tenovin-1 (IC 50 , 0.7 M), which protects against MDM2-mediated p53 degradation, MPA (IC 50 , 0.4 M), and gemcitabine (IC 50 , 0.3 M). MPA and gemcitabine have also been reported to be ZIKV inhibitors by others (26, 43) . A less potent effect was also observed in human brain microvascular endothelial cells (hBMECs), an immortalized model of the human blood-brain barrier micro vasculature that may be involved in ZIKV access to fetal brain. Furthermore, some of the semolecules were also active on Jeg 3 human placental cells.
Chloroquine is an anti-inflammatory FDA-approved 4-aminoquinoline widely used as an antimalaria drug and administered to pregnant women at risk of exposure to Plasmodium parasites, and has also shown antiviral activity against several viruses through the inhibition of pH-dependent steps of viral replication. This drug has been described to exhibit anti-ZIKV activity in Vero cells (44) . The agent also affected ZIKV-infected hBMECs, as well as human NSCs, for which the depletion of is one of the main mechanisms responsible for primary microcephaly (45) . Chloroquine reduced the number of ZIKV-infected cells, thereby inhibiting virus production (including of defective viral particles), and reduced cell death promoted by ZIKV infection, thus interfering with the early stages of the ZIKV replication cycle, possibly during the fusion of the envelope protein to the endosomal membrane (44) . The reported EC 50 s were 9.8 M, 14.2 M, and 12.3 M (for therapeutic indexes [TIs] of 13.7, 8.2, and 7.7) for Vero, hBMECs, and NSCs, respectively. Saliphenylhalamide (SaliPhe), which targets vacuolar ATPase and blocks the acidification of endosomes, also inhibits ZIKV replication in human retinal pigment epithelial (RPE) cells, which are natural targets for ZIKV infection (46) , with an EC 50 of 1 M and an SI of Ͼ200 (26). Interestingly, SaliPhe, chloroquine, and other compounds interfering with the endocytic pathway, such as dynasore and monensin, were also identified as potential anti-ZIKV compounds in a different screening (23) . In this line, it has also been reported that obatoclax, also known as GX15-070 (an inhibitor of the Bcl-2 family of proteins that targets cellular Mcl-1 and inhibits endocytosis, thereby inducing apoptosis), presented an EC 50 of 0.3 M and an SI of 65 and could impair ZIKV endocytic uptake, as well as several agents used for the treatment of cancers and with an already known capacity to inhibit multiplication of other viruses (26) .
Barrows and coworkers, after assaying an FDA-approved library of compounds, showed that over 20 of them reduced ZIKV infection in hepatoma-derived HuH-7 cells, including bortezomib (a selective inhibitor of proteasome activity used in patients with multiple myeloma), daptomycin (a lipopeptide antibiotic), MPA, sertraline, pyrimethamine, cyclosporine, azathioprine, and mefloquine (43) . Next, selected drugs were tested in human cervical cells (as ZIKV can be sexually transmitted, probably when infected semen comes in contact with the vaginal mucosa or the cervix [47] ), placental cells, neural stem cell lines, and primary human amnion cells, showing EC 50 s of 1 M (daptomycin), 0.1 M (MPA), and 1 to 10 M (ivermectin).
Another recent study of drug repurposing, based on the expression of the viral NS1 protein as a readout of anti-ZIKV activity for primary screening, tested over 5,000 compounds from the LOPAC (library of pharmacologically active compounds), the NCATS (National Center for Advancing Translational Sciences) pharmaceutical collection, and a collection of clinical candidates (48) . The study was conducted in ZIKV-infected glioblastoma SNB-19 cells, as well as in human NPCs and astrocytes, both of which are target cells for ZIKV infection in the fetal brain (49, 50) . Emricasan, a pan-caspase inhibitor currently in phase 2 clinical trials in chronic HCV patients, inhibited increases in caspase-3 activity induced by ZIKV infection and protected human NPCs in both monolayer and three-dimensional organoid cultures, showing neuroprotective activity but not suppressing viral replication. Emricasan also showed anti-cell death activity in SNB-19 cells (IC 50 , 0.1 to 0.9 M) and astrocytes (IC 50 , 0.2 M) . Likewise, niclosamide, a category B (and thus considered to be without risk to fetuses) anthelmintic drug approved by the FDA with a broad antiviral activity due to its ability to neutralize endolysosomal pH and interfere with pH-dependent membrane fusion (51), also inhibited ZIKV replication in a submicromolar range, as did PHA-690509, an investigational compound that functions as a cyclin-dependent kinase (CDK) inhibitor. This finding, as no CDKs encoded by flavivirus have been described, suggests that host cellular CDKs might be involved in ZIKV replication; however, these compounds are unlikely to be suitable for use in pregnant women because of their potentially hazardous effects on the fetus. As these two compounds (niclosamide and PHA-690509) were effective in ZIKV inhibition when added 1 h before or 4 h after viral inoculation, they probably affected a postviral entry step during viral replication (48) . In addition, emricasan and PHA-690509, with different mechanisms of action (neuroprotective and antiviral), when administered in combination, showed an additive effect in inhibiting caspase-3 activity in SNB-19 cells and astrocytes.
By means of a cell-based high-content screening assay, different FDA-approved molecules included in the National Institutes of Health (NIH) clinical collection compound library were reported to present moderate activity against ZIKV infection in Huh-7 cells (24) . Among these were palonosetron (EC 50 , 16.3 M; SI, Ͼ3.1), an antiemetic, kitasamycin (EC 50 , 41.7 M; SI, Ͼ12), a broad-spectrum antimicrobial, and lovastatin (EC 50 , 20.7 M; SI, Ͼ2.5), a hypolipidemic agent that inhibits cholesterol biosynthesis. Interestingly, other hypolipidemic agents targeting sterol-responsive element binding protein (SREBP) activity, such as nordihydroguaiaretic acid and its derivative, tetra-O-methyl nordihydroguaiaretic acid (M 4 N), an anticancer drug in clinical trials, PF-429242, and fatostatin, also reduced ZIKV infection in cultured Vero cells (T. Merino-Ramos, N. Jiménez de Oya, J.-C. Saiz, and M. A. Martín-Acebes, submitted for publication). Along this line, anti-ZIKV activity has also been reported for 25-hydroxycholesterol, which also regulates SREBP activity and is involved in the innate immune response to toll-like receptor ligands and interferon (52) . Importantly, 25-hydroxycholesterol inhibited ZIKV infection in vitro (IC 50 , 0.2 M) by blocking viral entry, reduced viremia and conferred protection against ZIKV in mice and rhesus macaques, and reduced tissue damage in human cortical organoids and the embryonic brains of infected mice (52) . Finally, an additional study has identified three antimalarial compounds that inhibited ZIKV in Vero cells, namely, quinacrine (EC 50 , 2.3 M), mefloquine (EC 50 , 3.9 M), and GSK369796 (EC 50 , 2.8 M) (53) .
CONCLUSIONS
During the past months, the scientific community has made an enormous effort in the search for antiviral candidates to fight ZIKV infection. To do so, different approaches and methodologies have been used, from testing specific compounds with known antiviral activity in other virus models, to libraries composed of hundreds of bioactive molecules, many of them already approved for human use. These molecules target viral and cellular components and included nucleosides analogues, nucleoside synthesis inhibitors, drugs targeting viral enzymes, anticancer and anti-inflammatory molecules, antibiotics, antiparasitics, and so on. In any case, care should be taken as, in many instances, the described in vitro antiviral activities are difficult to extrapolate to their possible use in humans, as only a few have been assayed in immunodeficient mouse models and only one has been assayed in nonhuman primates. Taking into account that the main target populations for antiviral therapy will be people with underlying medical conditions and pregnant women, these drugs could have untoward effects, and thus, careful evaluation should be conducted before using them in clinical practice.
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